PT-141 Side Effects: What You Need to Know

PT-141 (bremelanotide) is one of the better-studied peptides when it comes to safety data. Two Phase 3 clinical trials, a 52-week extension study, and years of post-market surveillance give us a clear picture of what to expect — and what to watch for.

If you’re considering peptide therapy with PT-141 for sexual dysfunction, this guide covers every documented side effect, how common each one actually is, and practical strategies for managing them. If you’re still deciding whether PT-141 is right for you, our guide on peptides for libido compares all the options. For background on what PT-141 does and who it’s for, see our PT-141 for women guide.

Key Takeaways

• Nausea is the most common side effect (~40% of users) but typically improves after the first dose
• Flushing affects about 20% of users and is usually mild and brief
• PT-141 causes small, temporary blood pressure increases (2-3 mmHg) that resolve within hours
• Skin darkening (hyperpigmentation) occurs in ~1% of users and may not fully reverse
• No serious safety signals emerged in 52-week long-term follow-up

Table of Contents

• Common Side Effects
• Nausea: The Big One
• Flushing and Hot Flashes
• Blood Pressure Changes
• Injection Site Reactions
• Skin Darkening (Hyperpigmentation)
• Headache
• Less Common Side Effects
• Long-Term Safety Data
• How to Minimize Side Effects
• When to Stop Using PT-141
• FAQ
• Sources

Common Side Effects

The RECONNECT Phase 3 trials enrolled over 1,200 women and tracked side effects rigorously. Here’s the complete picture from the FDA-approved prescribing information [1]:

Side Effect	PT-141 (n=636)	Placebo (n=614)
Nausea	40.0%	1.3%
Flushing	20.3%	1.3%
Injection site reactions	13.2%	8.6%
Headache	11.3%	6.3%
Vomiting	4.8%	0.2%
Cough	3.3%	0.3%
Fatigue	3.2%	1.0%
Hot flash	2.7%	0.2%
Nasal congestion	2.5%	0.7%
Upper respiratory infection	2.4%	2.3%
Dizziness	2.0%	0.5%
Hyperpigmentation	1.3%	0%

A few things stand out. Nausea and flushing are clearly drug-related (huge gap vs. placebo). Headache and injection site reactions are partially drug-related. And things like upper respiratory infections are just background noise — no difference from placebo.

Nausea: The Big One

Let’s be direct: 40% is a high nausea rate. That’s the single biggest barrier to PT-141 use, and it deserves honest discussion.

What the Nausea Feels Like

Most women describe it as a wave of queasiness that begins 30-60 minutes after injection and lasts 1-2 hours. It’s rarely severe enough to cause actual vomiting (less than 5% of users vomit), but it’s unpleasant enough to dampen the mood you were trying to create [1].

The Good News: It Gets Better

Here’s what the clinical data actually shows about nausea over time:

• The first dose produces the worst nausea in most women
• By the second and third doses, nausea severity drops significantly
• Many women who initially experience nausea find it manageable or absent by dose 4-5 [1]

The prescribing information specifically notes that “nausea is more likely to occur with the initial dose” [1]. This isn’t just reassurance — the data backs it up. Women who pushed through the first few doses often found the side effect tolerable.

Managing Nausea

Strategies that help:

1. Ondansetron (Zofran) — Take 4-8 mg about 30 minutes before PT-141. This is specifically mentioned in the FDA label as a management strategy [1].
2. Light meal beforehand — Don’t inject on a completely empty stomach, but avoid heavy meals too.
3. Ginger — Ginger tea or ginger chews before and after injection. Less evidence than ondansetron but low risk.
4. Timing — Some women find that injecting earlier (60-90 minutes before) gives the nausea time to pass before activity.

Flushing and Hot Flashes

About 20% of women experience flushing — a sudden warmth and redness, typically in the face, neck, and chest [1]. An additional 2.7% report hot flashes.

Flushing is caused by PT-141’s activation of melanocortin receptors, which play a role in regulating body temperature and blood vessel dilation. It’s the same pathway that produces the drug’s therapeutic effects, so you can’t really separate the two.

The flushing is almost always:

• Mild to moderate in intensity
• Brief (15-45 minutes)
• Not medically concerning

Most women describe it as similar to a hot flash or the feeling of mild embarrassment. It doesn’t require treatment and isn’t a reason to discontinue unless it’s personally bothersome.

Blood Pressure Changes

PT-141 causes a small, transient increase in blood pressure. This is the side effect that raises the most medical concern, even though it’s clinically mild in healthy individuals.

The Numbers

In clinical trials, the average blood pressure increase was:

• Systolic: +2 to 3 mmHg
• Diastolic: +1 to 2 mmHg

The increase typically peaks 2-4 hours after injection and returns to baseline within 12 hours [1].

Why It Matters

A 2-3 mmHg bump is nothing for a healthy person. But for someone with uncontrolled hypertension or cardiovascular disease, even small transient increases can be problematic. That’s why PT-141 is contraindicated in people with uncontrolled high blood pressure [1].

If you have treated, well-controlled hypertension, PT-141 may still be an option — but your prescriber needs to know about it. Home blood pressure monitoring after the first few doses is a reasonable precaution.

This is a common consideration with many peptide therapies. Understanding your baseline cardiovascular status matters before starting any new treatment.

Injection Site Reactions

About 13% of PT-141 users reported injection site reactions, compared to 8.6% on placebo [1]. This is a relatively small difference, meaning much of it is just the normal response to any subcutaneous injection.

Typical reactions include:

• Mild redness at the injection site
• Small bruise
• Temporary itching or swelling

These are standard for any subcutaneous peptide injection and usually resolve within 24-48 hours. Rotating injection sites (alternating between left and right abdomen or thighs) helps minimize local reactions.

Skin Darkening (Hyperpigmentation)

This is the most unusual side effect of PT-141, and it’s directly related to how the drug works. Melanocortin receptors control both sexual response AND melanin production. You can’t fully activate one without some potential effect on the other.

About 1.3% of women in clinical trials developed focal hyperpigmentation — darkening of specific skin areas, most commonly [1]:

• Face (especially cheeks)
• Gums
• Breasts

Important Details

• The darkening tends to develop gradually over weeks to months of use
• It may not fully reverse after stopping PT-141
• It’s cosmetic only — not medically harmful
• Higher cumulative doses increase the risk

The FDA label recommends limiting use to no more than 8 doses per month, partly to reduce hyperpigmentation risk [1]. If you notice new skin darkening, discuss it with your provider. It doesn’t require emergency action but may influence the decision to continue treatment.

Headache

Headache occurred in 11.3% of PT-141 users vs. 6.3% on placebo [1]. The drug-attributable rate is therefore about 5% — modest but real.

PT-141 headaches are typically:

• Mild to moderate
• Similar to a tension headache
• Short-lived (1-3 hours)
• Responsive to standard OTC pain relief

If you’re prone to migraines, discuss this with your provider before starting PT-141. There’s no specific data on PT-141 triggering migraines, but the vasodilatory effects could theoretically lower the threshold.

Less Common Side Effects

These occurred in fewer than 2% of PT-141 users in clinical trials [1]:

• Fatigue (3.2%) — Some women feel mildly tired after the drug’s effects wear off
• Cough (3.3%) — Mechanism unclear, possibly related to nasal congestion
• Nasal congestion (2.5%) — Related to vasodilation
• Dizziness (2.0%) — Usually brief, likely related to blood pressure changes
• Back pain, abdominal pain, arthralgia — Each occurred at rates barely above placebo

No liver toxicity has been associated with PT-141 at approved doses [2]. No effects on fertility have been documented in clinical studies.

Long-Term Safety Data

The 52-week open-label extension of the RECONNECT trials provides the best long-term safety picture. Over 684 women continued using PT-141 for up to a year [3].

Key findings:

• No new safety signals emerged beyond what was seen in the 24-week trials
• No dose escalation was needed — women continued responding to the same 1.75 mg dose
• No withdrawal effects occurred when women stopped using PT-141
• Cardiovascular safety was maintained — no heart events attributable to the drug
• Average use was 2-3 times per month, not daily

The long-term data is reassuring. PT-141 doesn’t appear to cause tolerance, dependence, or cumulative organ damage at approved doses over one year [3].

For context on how PT-141’s safety profile compares to other peptides, see our overview of whether peptides are safe.

How to Minimize Side Effects

Based on clinical data and prescriber experience, here’s how to have the best experience with PT-141:

First Dose Strategy

Your first dose will likely produce the strongest side effects. Plan accordingly:

• Take ondansetron (if prescribed) 30 minutes before
• Have a light meal 1-2 hours before injecting
• Choose a relaxed evening without time pressure
• Don’t judge the medication by dose #1 alone — give it 3-4 tries

Ongoing Use

• Rotate injection sites to minimize local reactions
• Stay hydrated — dehydration worsens nausea and headache
• Don’t exceed 8 doses per month — this is both for efficacy and safety
• Monitor your skin for any new darkening, especially with ongoing use
• Check blood pressure periodically if you have any cardiovascular risk factors

What Doesn’t Help

• Taking a higher dose doesn’t work better and increases side effects
• Taking PT-141 more frequently than every 24 hours increases risk without benefit
• Combining PT-141 with alcohol doesn’t change PT-141’s pharmacokinetics, but alcohol-related nausea can stack with PT-141-related nausea [4]

When to Stop Using PT-141

Discontinue PT-141 and contact your healthcare provider if you experience:

• Severe, persistent nausea or vomiting that doesn’t improve over several doses
• Sustained blood pressure elevation (not just the normal transient bump)
• Significant skin darkening that concerns you
• Any allergic reaction (rash, swelling, difficulty breathing)
• No improvement in symptoms after 8 weeks of appropriate use

PT-141 has no withdrawal effects. You can stop at any time without tapering [1].

Explore the evidence: See all 8 PT-141 studies in our research database, or browse the full peptide therapy statistics for 2026.

FAQ

Does PT-141 nausea go away over time?▼

Yes, for most women. The first dose tends to produce the strongest nausea. By the third or fourth dose, many women report that nausea is significantly reduced or absent. The FDA prescribing information specifically notes this pattern. Taking ondansetron beforehand helps bridge the early doses [1].

Can PT-141 cause permanent skin darkening?▼

Focal hyperpigmentation occurs in about 1.3% of users and may not fully reverse after stopping the medication. The risk increases with cumulative dosing, which is one reason the FDA recommends no more than 8 doses per month. If you notice new darkening, discuss with your provider [1].

Is PT-141 safe for the heart?▼

PT-141 causes small, transient blood pressure increases (2-3 mmHg) that resolve within 12 hours. In clinical trials involving over 1,200 women, no cardiovascular events were attributed to the drug. However, it’s contraindicated in people with uncontrolled hypertension [1, 3].

What are the side effects of PT-141 in men?▼

PT-141 has been studied in men for erectile dysfunction, though it’s not FDA-approved for male use. In male studies, side effects were similar: nausea, flushing, and headache. Men also experienced transient blood pressure increases. The side effect profile appears comparable between sexes [5].

Can you drink alcohol with PT-141?▼

A Phase 1 study found that alcohol doesn’t significantly change PT-141’s pharmacokinetics [4]. However, alcohol can worsen nausea, which is already the most common PT-141 side effect. Moderate alcohol use is not contraindicated (unlike flibanserin), but heavy drinking before PT-141 isn’t advisable.

Sources

1. Vyleesi (bremelanotide injection) prescribing information. AMAG Pharmaceuticals, Inc; 2019. FDA Label

2. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bremelanotide. National Institute of Diabetes and Digestive and Kidney Diseases; 2021. NCBI Bookshelf

3. Simon JA, Kingsberg SA, Portman D, et al. Long-term safety and efficacy of bremelanotide for hypoactive sexual desire disorder. Obstet Gynecol. 2019;134(5):909-917. PMC

4. Patel M, Gould P, Engel H, et al. Phase I randomized placebo-controlled, double-blind study of the safety and tolerability of bremelanotide coadministered with ethanol. Clin Ther. 2017;39(3):514-526. ScienceDirect

5. Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res. 2004;16(1):51-59. PubMed

6. Kingsberg SA, Clayton AH, Pfaus JG, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstet Gynecol. 2019;134(5):899-908. PMC